Further experiments confirmed that inhibiting ASNS or combining L-asparaginase with rapamycin significantly blocks KRAS-mutant tumor proliferation, indicating ASNS-driven asparagine synthesis is key to metabolic adaptation and therapy resistance in KRAS-mutant CRC [33]. The gene discussed is KRAS; the disease is neoplasm.